Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hemagen (US) gets Chagas approval:

This article was originally published in Clinica

Executive Summary

Hemagen (US) has received FDA approval to market its Chagas' disease ELISA. Chagas' disease, a progressively debilitating, insect-borne parasitic disease, can be transmitted through blood transfusions and usually kills its victims within ten years. Testing is routine in Latin American blood banks, but not in the US. The test is already marketed in South America by German major Boehringer Mannheim (see Clinica No 583, p 3), and in Brazil under Hemagen's own label. As many as 7% of the South American population have Chagas' disease.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT091822

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel